Pages that link to "Q36895413"
Jump to navigation
Jump to search
The following pages link to Small molecule signal transduction inhibitors for the treatment of solid tumors (Q36895413):
Displaying 11 items.
- Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity (Q26992272) (← links)
- Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways (Q33582914) (← links)
- Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas (Q33691544) (← links)
- Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors (Q35091502) (← links)
- Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries (Q35747269) (← links)
- Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. (Q37152009) (← links)
- HtrA serine proteases as potential therapeutic targets in cancer (Q37515512) (← links)
- Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer (Q39887307) (← links)
- Targeted medical therapy of biliary tract cancer: recent advances and future perspectives (Q42635172) (← links)
- Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives (Q43097453) (← links)
- Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer (Q43141124) (← links)